Kiromic Biopharma, Inc. Proceeds from Convertible Debt
Kiromic Biopharma, Inc. reported Proceeds from Convertible Debt of $18.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2025-02-14
- Kiromic Biopharma, Inc. proceeds from convertible debt for the quarter ending 2024-12-31 was $2.00M, a 54.55% decline year-over-year.
- Kiromic Biopharma, Inc. proceeds from convertible debt for the quarter ending 2024-09-30 was $1.12M, a 84.40% decline year-over-year.
- Kiromic Biopharma, Inc. proceeds from convertible debt for the quarter ending 2024-06-30 was $8.88M, a 38.70% increase year-over-year.
- Kiromic Biopharma, Inc. proceeds from convertible debt for the quarter ending 2024-03-31 was $6.00M, a 0.00% change year-over-year.
- Kiromic Biopharma, Inc. proceeds from convertible debt for fiscal 2024 was $18.00M, a 25.00% decline from fiscal 2023.
- Kiromic Biopharma, Inc. proceeds from convertible debt for fiscal 2023 was $24.00M, a 500.00% increase from fiscal 2022.
- Kiromic Biopharma, Inc. proceeds from convertible debt for fiscal 2022 was $4.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $3.12M derived: sum of 2 quarters · filed 2025-02-14 | $12.00M derived: sum of 3 quarters · filed 2025-02-14 | $18.00M 10-K · filed 2025-02-14 |
| 2024-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $10.00M derived: sum of 2 quarters · filed 2024-11-08 | $16.00M 10-Q · filed 2024-11-08 | $20.40M derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-06-30 | $8.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $14.88M 10-Q · filed 2024-08-09 | $19.28M derived: sum of 3 quarters · filed 2025-02-14 | $26.48M derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-03-31 | $6.00M 10-Q · filed 2024-05-10 | $10.40M derived: sum of 2 quarters · filed 2025-02-14 | $17.60M derived: sum of 3 quarters · filed 2025-02-14 | $24.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $11.60M derived: sum of 2 quarters · filed 2025-02-14 | $18.00M derived: sum of 3 quarters · filed 2025-02-14 | $24.00M 10-K · filed 2025-02-14 |
| 2023-09-30 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $13.60M derived: sum of 2 quarters · filed 2024-11-08 | $19.60M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $12.40M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $6.00M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $4.00M 10-K · filed 2024-03-19 |